AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,042.00p
   
  • Change Today:
    -164.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.29m
  • Volume: 2,329,887
  • Market Cap: £171,184m
  • RiskGrade: 123

AstraZeneca sells US manufacturing site

By Abigail Townsend

Date: Wednesday 30 Nov 2022

LONDON (ShareCast) - (Sharecast News) - AstraZeneca has agreed to sell a US manufacturing site to National Resilience.
Resilience, a US biomanufacturing company, is buying the West Chester site in Ohio, a commercial scale, 580,000sq ft facility.

Resilience will continue to manufacture select AstraZeneca medicines at the site as part of a multi-year agreement, and will retain the site's management and employees. Around 500 people work at West Chester.

Andrew Wirths, AstraZeneca senior vice president, Americas supply region, said: "As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio.

"The transfer of our West Chester site to Resilience will enable the continued supply of AstraZeneca medicines to patients."

Rahul Singhvi, chief executive of Resilience, said the site would enable it to "broaden our access to complex medicines, protect biopharmaceutical supply chains, and strengthen domestic preparedness".

The transaction is expected to close in early 2023. Financial terms were not disclosed.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,042.00p
Change Today -164.00p
% Change -1.46 %
52 Week High 13,276.00p
52 Week Low 9,501.00p
Volume 2,329,887
Shares Issued 1,550.29m
Market Cap £171,184m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average
52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average
Income
88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Growth
88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 31-Oct-2024

Time Volume / Share Price
16:09 179,211 @ 11,160.00p
16:51 488 @ 11,042.00p
16:51 142 @ 11,042.00p
16:35 3,725 @ 11,042.00p
16:35 75 @ 11,042.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page